Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

DSpace/Manakin Repository

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status
 
van Breeschoten, Jesper; Wouters, Michel W J M; de Wreede, Liesbeth C; Hilarius, Doranne H; Haanen, John B; Blank, Christian U; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; de Groot, Jan-Willem B; Hospers, Geke A P; Kapiteijn, Ellen; Piersma, Djura; van Rijn, Rozemarijn S; Suijkerbuijk, Karijn P M; Blokx, Willeke A M; Ten Tije, Albert J; van der Veldt, Astrid A M; Vreugdenhil, Gerard; Boers, Marye J; van den Eertwegh, Alfons J M
(2021) American Journal of Clinical Oncology, volume 44, issue 2, pp. 82 - 89
(Article)
Abstract
OBJECTIVE: The aim of this study was to evaluate treatment patterns and overall survival (OS) of patients with BRAFV600 wild-type and BRAFV600-mutant advanced melanoma in the Netherlands. METHODS: We selected patients of 18 years and over, diagnosed between 2016 and 2017 with unresectable stage IIIC or IV melanoma, registered in ... read more
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: BRAF mutation, BRAF/MEK inhibitors, CTLA-4 inhibitor, National Registry, advanced melanoma, anti-PD-1-ligands, checkpoint inhibitors, Oncology, Cancer Research
DOI: https://doi.org/10.1097/COC.0000000000000786
ISSN: 0277-3732
Publisher: Lippincott Williams & Wilkins
Note: Funding Information: For the Dutch Melanoma Treatment Registry (DMTR), the Dutch Institute for Clinical Auditing Foundation received a startup grant from the governmental organization The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, and Roche Pharma. Roche Pharma stopped funding in 2019 and Pierre Fabre started funding of the DMTR in 2019. Funding Information: J.B.H. has advisory relationships with Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celsius Therapeutics, GSK, Immunocore, Ipsen, MSD, Merck Serono, Novartis, Neon Therapeutics, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics and has received research grants not related to this paper from Novartis, Bristol-Myers Squibb, MSD, Neon Therapeutics. All grants were paid to the institutions. C.U.B. has advisory relationships with, Bristol-Myers Squibb, Genmab, GSK, Lilly, MSD, Roche, Novartis, Pfizer and grant support by BMS, Novartis, and NanoString. J.-W.B.d.G. has received personal fees outside the submitted work from Bristol-Myers Squibb, Roche, Pierre Fabre, Servier, MSD, Novartis. G.A.P.H. has consultancy/advisory relationships with Amgen, Bristol-Myers Squibb, Roche, MSD, Pfizer, Novartis, BMS. She received honoraria from Novartis, Pierre Fabre, and Roche and has received research grants not related to this paper from Bristol-Myers Squibb, Seerave. A.A.M.v.d.V. has consultancy relationships with Bristol-Myers Squibb, MSD, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Ipsen, Eisai. E.K. has consultancy/advisory relationships with Amgen, Bristol-Myers Squibb, Novartis, Roche, Merck, Pierre Fabre, EISAI, Bayer, Genzyme-Sanofi and received research grants not related to this paper from Novartis and Bristol-Myers Squibb. K.P.M.S. has consulting/advisory relationships with BMS and MSD. She received honoraria from Novartis, Pierre Fabre, and Roche. A.J.M.v.d.E. has consulting/advisory relationships with BMS, Roche, MSD, and Novartis. He received a study grant from Roche. The funders had no role in the writing of this article or decision to submit it for publication. The other authors declare no conflicts of interest. Publisher Copyright: © 2021 Lippincott Williams and Wilkins. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
(Peer reviewed)